Skip to main content
Top
Published in: Annals of Behavioral Medicine 1/2011

01-08-2011 | Rapid Communication

Clinician-Assessed Depression and HAART Adherence in HIV-Infected Individuals in Methadone Maintenance Treatment

Authors: Jeffrey S. Gonzalez, Ph.D., Christina Psaros, Ph.D., Abigail Batchelder, M.P.H., Allison Applebaum, Ph.D., Howard Newville, M.A., Steven A. Safren, Ph.D.

Published in: Annals of Behavioral Medicine | Issue 1/2011

Login to get access

Abstract

Background

The impact of measurement methods on the relationship between depression and HIV treatment adherence has not been adequately examined.

Purpose

The purpose of this paper is to examine the relationship between clinician- and patient-rated depression and HIV medication adherence.

Methods

The participants were 91 HIV-infected individuals in methadone maintenance. Depression was assessed via clinician ratings (Clinical Global Impression Scale and Montgomery Asberg Depression Rating Scale) and self-report (Beck Depression Inventory-Short Form). Clinicians rated substance abuse using the Clinical Global Impression Scale and a structured interview. HIV medication adherence was measured over the following 2 weeks using electronic caps.

Results

Each unit increase in the Clinical Global Impression Scale was associated with 75% increased odds of nonadherence (OR = 1.75, p = 0.002, 95% CI = 1.23–2.48). Similarly, for each standard deviation Montgomery Asberg Depression Rating Scale increase, there was a 2.6-fold increased odds of nonadherence (OR = 2.60, p = 0.001, 95% CI = 1.45–4.67). Substance abuse and self-reported depression severity were not significantly related to adherence.

Conclusions

Clinician-rated depression severity was a strong predictor of nonadherence. Assessment methods may influence the relationship between depression and HIV nonadherence.
Literature
1.
go back to reference Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acq Immun Def Synd. 2006; 41(2): 194–200.CrossRef Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acq Immun Def Synd. 2006; 41(2): 194–200.CrossRef
2.
go back to reference Glass TR, De Geest S, Hirschel B, et al. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther. 2008; (13): 77–85. Glass TR, De Geest S, Hirschel B, et al. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther. 2008; (13): 77–85.
3.
go back to reference DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment - Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000; 160(14): 2101–2107.PubMedCrossRef DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment - Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000; 160(14): 2101–2107.PubMedCrossRef
4.
go back to reference Bing EG, Burnam A, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiat. 2001; 58(8): 721–728.PubMedCrossRef Bing EG, Burnam A, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiat. 2001; 58(8): 721–728.PubMedCrossRef
5.
go back to reference Tucker JS, Burnam MA, Sherbourne CD, Kuong F, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003; 114(7): 573–580.PubMedCrossRef Tucker JS, Burnam MA, Sherbourne CD, Kuong F, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003; 114(7): 573–580.PubMedCrossRef
6.
go back to reference Wagner GJ. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care ST. 2002; 16(12): 599–608.CrossRef Wagner GJ. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care ST. 2002; 16(12): 599–608.CrossRef
7.
go back to reference Gibbie T, Hay M, Hutchison CW, Mijch A. Depression, social support and adherence to highly active antiretroviral therapy in people living with HIV/AIDS. Sexual Health. 2007; 4(4): 227–232.PubMedCrossRef Gibbie T, Hay M, Hutchison CW, Mijch A. Depression, social support and adherence to highly active antiretroviral therapy in people living with HIV/AIDS. Sexual Health. 2007; 4(4): 227–232.PubMedCrossRef
8.
go back to reference Gonzalez JS, Penedo FJ, Antoni MH et al. Social support, positive states of mind, and HIV treatment adherence in men and women living with HIV/AIDS. Health Psychol. 2004; 23(4): 413–418.PubMedCrossRef Gonzalez JS, Penedo FJ, Antoni MH et al. Social support, positive states of mind, and HIV treatment adherence in men and women living with HIV/AIDS. Health Psychol. 2004; 23(4): 413–418.PubMedCrossRef
9.
go back to reference O’Cleirigh C, Ironson G, Weiss A, Costa PT. Conscientiousness predicts disease progression (CD4 Number and Viral Load) in people living with HIV. Health Psychol. 2007; 26(4): 473–480.PubMedCrossRef O’Cleirigh C, Ironson G, Weiss A, Costa PT. Conscientiousness predicts disease progression (CD4 Number and Viral Load) in people living with HIV. Health Psychol. 2007; 26(4): 473–480.PubMedCrossRef
10.
go back to reference Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004; 45(5): 394–402.PubMedCrossRef Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004; 45(5): 394–402.PubMedCrossRef
11.
go back to reference Arnsten JH, Li X, Mizuno Y, et al. Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. J Acq Immun Def Synd. 2007; 46: S64–S71.CrossRef Arnsten JH, Li X, Mizuno Y, et al. Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. J Acq Immun Def Synd. 2007; 46: S64–S71.CrossRef
12.
go back to reference Avants SK, Margolin A, Warburton LA, Hawkins KA. Predictors of nonadherence to HIV-related medication regimes during methadone stabilization. Am J Addiction. 2001; 10:69–78.CrossRef Avants SK, Margolin A, Warburton LA, Hawkins KA. Predictors of nonadherence to HIV-related medication regimes during methadone stabilization. Am J Addiction. 2001; 10:69–78.CrossRef
13.
go back to reference Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV+ drug users. J Gen Intern Med. 2002; 17(5): 377–381.PubMed Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV+ drug users. J Gen Intern Med. 2002; 17(5): 377–381.PubMed
14.
go back to reference Berg K, Demas P, Howard A, Schoenbaum E, Gourevitch M, Arnsten J. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med. 2004; 19(11): 1111–1117.PubMedCrossRef Berg K, Demas P, Howard A, Schoenbaum E, Gourevitch M, Arnsten J. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med. 2004; 19(11): 1111–1117.PubMedCrossRef
15.
go back to reference Beck AT. Cognitive therapy of depression. 1979; The Guilford Press: New York, NY. Beck AT. Cognitive therapy of depression. 1979; The Guilford Press: New York, NY.
16.
go back to reference Matt GE, Vázquez C, Campbell KW. Mood-congruent recall of affectively toned stimuli: A meta-analytic review. Clin Psychol Rev. 1992; 12(2): 227–255. Matt GE, Vázquez C, Campbell KW. Mood-congruent recall of affectively toned stimuli: A meta-analytic review. Clin Psychol Rev. 1992; 12(2): 227–255.
17.
go back to reference Hansen RA, Dusetzina SB, Song L, Gaynes BN, Tu W, Murray MD. Depression affects adherence measurement but not the effectiveness of an adherence intervention in heart failure patients. J Am Pharm Assoc. 2009, 49(6): 760–768.CrossRef Hansen RA, Dusetzina SB, Song L, Gaynes BN, Tu W, Murray MD. Depression affects adherence measurement but not the effectiveness of an adherence intervention in heart failure patients. J Am Pharm Assoc. 2009, 49(6): 760–768.CrossRef
18.
go back to reference Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiat. 1998; 59(Suppl 20): 22–33. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiat. 1998; 59(Suppl 20): 22–33.
19.
go back to reference Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiat. 1979; 13(4): 382–389.CrossRef Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiat. 1979; 13(4): 382–389.CrossRef
20.
go back to reference Guy W. Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH. 1976; 218–222. Guy W. Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH. 1976; 218–222.
21.
go back to reference Beck AT, Rial WY, Rickels K. Short form of depression inventory: Cross-validation. Psychol Rep. 1974; 34(3):1184–1186.PubMed Beck AT, Rial WY, Rickels K. Short form of depression inventory: Cross-validation. Psychol Rep. 1974; 34(3):1184–1186.PubMed
22.
go back to reference Reynolds WM, Gould JW. A psychometric investigation of the standard and short form Beck Depression Inventory. J Consult Clin Psych. 1981; 49(2): 306–307.CrossRef Reynolds WM, Gould JW. A psychometric investigation of the standard and short form Beck Depression Inventory. J Consult Clin Psych. 1981; 49(2): 306–307.CrossRef
23.
go back to reference McLellan AT, Luborsky L, Woody GE, O’Brien CP. An improved diagnostic evaluation instrument for substance abuse patients: The Addiction Severity Index. J Nerv Ment Dis. 1980; 168(1): 26–33.PubMedCrossRef McLellan AT, Luborsky L, Woody GE, O’Brien CP. An improved diagnostic evaluation instrument for substance abuse patients: The Addiction Severity Index. J Nerv Ment Dis. 1980; 168(1): 26–33.PubMedCrossRef
Metadata
Title
Clinician-Assessed Depression and HAART Adherence in HIV-Infected Individuals in Methadone Maintenance Treatment
Authors
Jeffrey S. Gonzalez, Ph.D.
Christina Psaros, Ph.D.
Abigail Batchelder, M.P.H.
Allison Applebaum, Ph.D.
Howard Newville, M.A.
Steven A. Safren, Ph.D.
Publication date
01-08-2011
Publisher
Springer-Verlag
Published in
Annals of Behavioral Medicine / Issue 1/2011
Print ISSN: 0883-6612
Electronic ISSN: 1532-4796
DOI
https://doi.org/10.1007/s12160-011-9268-y

Other articles of this Issue 1/2011

Annals of Behavioral Medicine 1/2011 Go to the issue